UPDATED: Amgen's Kyprolis beats Janssen's Velcade in multiple myeloma …
Amgen’s Kyprolis has beaten Janssen’s Velcade on progression-free survival in patients with relapsed or refractory multiple myeloma taking part in the Phase III Endeavor trial. - News - PharmaTimes
by Janet Fricker
https://www.pharmatimes.com/news/updated_amgens_kyprolis_beats_janssens_velcade_in_multiple_myeloma_trial_972302